Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.

BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. RESEARCH QUESTION: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? STUDY DESIGN AND METHODS: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). RESULTS: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). INTERPRETATION: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. CLINICAL TRIALS REGISTRATION: NCT04521322.

[Toxocara canis and bronchial asthma]. / Toxocara canis y asma bronquial.

In order to evaluate the association between the infection by Toxocara canis and the symptoms of asthma in children from a subtropical region with high prevalence of toxocariasis, 47 asthmatic children and 53 non-asthmatics as a control group were studied. A complete physical examination was performed and clinical and epidemiological data were registered. In asthmatic children the frequency and severity of symptoms were classified in grades I to IV. The presence of anti-Toxocara canis antibodies in both groups was evaluated employing a solid phase ELISA method with excretion/secretion antigens, and total Ig E was also measured. Results showed a total seropositivity of 55%, 57.4% in children with asthma and 52.8% in the control group. Among asthmatics with severe symptoms (grade II, III and IV), there was a 67.7% of seropositivity while in children with symptoms of grade I there was a 37.5% (p = 0.0470). The infection with T. canis could act as a co-factor increasing the severity of the symptoms of bronchial asthma.

Toxocara canis y asma bronquial / Toxocara canis and bronchial asthma

A fin de evaluar la relación entre la infección por Toxocara canis y los síntomas del asma bronquial en niños de una región subtropical con alta prevalencia de toxocariosis, se estudiaron 47 niños con asma y 53 sin asma como grupo control. Se efectuó el examen físico completo, registrándose datos clínicos y epidemiológicos. En los niños con asma se categorizó el patrón de presentación, frecuencia y gravedad de los síntomas con una escala de I a IV. Se investigó la presencia de anticuerpos anti-Toxocara canis en ambos grupos mediante el método de ELISA en fase sólida, empleando antígeno de excreción/secreción y se efectuó dosaje de Ig E total. Los resultados muestran una seropositividad del 55% en el total de los niños, del 57.4% en los niños con asma y del 52.8% en los controles. En los niños con sintomatología más grave (grado II, III y IV) hubo un 67.7% de seropositivos, mientras que en los niños con síntomas de grado I la seropositividad fue de 37.5% (p = 0.0470). La infección por T. canis actuaría como un co-factor agravante de los síntomas del asma bronquial.

In order to evaluate the association between the infection by Toxocara canis and the symptoms of asthma in children from a subtropical region with high prevalence of toxocariasis, 47 asthmatic children and 53 non-asthmatics as a control group were studied. A complete physical examination was performed and clinical and epidemiological data were registered. In asthmatic children the frequency and severity of symptoms were classified in grades I to IV. The presence of anti-Toxocara canis antibodies in both groups was evaluated employing a solid phase ELISA method with excretion/secretion antigens, and total Ig E was also measured. Results showed a total seropositivity of 55%, 57.4% in children with asthma and 52.8% in the control group. Among asthmatics with severe symptoms (grade II, III and IV), there was a 67.7% of seropositivity while in children with symptoms of grade I there was a 37.5% (p = 0.0470). The infection with T. canis could act as a co-factor increasing the severity of the symptoms of bronchial asthma.